Testing abiraterone and prednisone for metastatic prostate cancer by race
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by lab testing, and it has spread to bones and/or other areas.
- You have had scans of all known disease (like a bone scan or PET) within the last 6 weeks.
- You can start this treatment soon after starting hormone-blocking therapy (usually not more than about 6 weeks), or you are willing to switch to it.
- Your PSA blood test is high enough (at least 10).
- Your heart and organ tests (liver, kidneys, blood counts, heart rhythm) are within required safety ranges.
- You have no brain metastases and no certain prior or planned prostate cancer treatments that conflict with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This trial tests whether a new version of the drug abiraterone (abiraterone acetate II) works as well as the standard version for men with metastatic castration-resistant prostate cancer (MCRPC) that has progressed. You may qualify if you have already had one type of hormone therapy or chemotherapy and your cancer is spreading.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.